The weight loss drug market exploded in 2026 with new formulations, higher doses, and a blockbuster newcomer. CagriSema, Novo Nordisk's next-generation combination drug, is heading toward FDA approval — but does it actually beat the incumbents? We compared CagriSema, Ozempic, Wegovy, and Zepbound across efficacy, side effects, cost, and availability to help you understand which drug delivers the most weight loss and which one you can actually get.
::keyfacts
- CagriSema achieves 22.7% weight loss in 68 weeks — but lost to Zepbound in a head-to-head trial
- Wegovy HD (7.2 mg), approved March 2026, delivers 20.7% weight loss — the strongest approved Wegovy injection yet
- Zepbound (tirzepatide) remains the weight loss leader at 22.5–25.5% reduction at max dose
- Oral Wegovy pill launched January 2026 at $149/month — first GLP-1 pill for weight loss
- CagriSema FDA decision expected late 2026; not yet available to patients ::/keyfacts
How These Drugs Work
All four medications target the GLP-1 receptor, which regulates appetite and blood sugar. But they do it differently — and that difference matters for results.
Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. The difference is labeling: Ozempic is approved for type 2 diabetes, while Wegovy is approved specifically for weight management. Same molecule, different indications.
Zepbound (tirzepatide) is a dual GLP-1 and GIP receptor agonist made by Eli Lilly. By hitting two receptors instead of one, it generally produces stronger appetite suppression and greater weight loss than semaglutide alone.
CagriSema combines semaglutide with cagrilintide, a long-acting amylin analogue. Amylin is a hormone your pancreas releases alongside insulin that slows stomach emptying and signals fullness. The theory: two mechanisms working together should outperform semaglutide alone.
Weight Loss Results Compared
This is what everyone wants to know. Here's how they stack up based on clinical trial data:
| Drug | Avg. Weight Loss | Trial Duration | Key Trial |
|---|---|---|---|
| Zepbound (15 mg) | 22.5–25.5% | 72–84 weeks | SURMOUNT / REDEFINE 4 |
| CagriSema (2.4 mg) | 22.7% (68 wk) / 23.0% (84 wk) | 68–84 weeks | REDEFINE 1 & 4 |
| Wegovy HD (7.2 mg) | 20.7% | 72 weeks | STEP UP |
| Wegovy (2.4 mg) | 15–17% | 68 weeks | STEP 1–4 |
| Oral Wegovy (25 mg pill) | 13.6% | 64 weeks | OASIS 4 |
| Ozempic (2 mg) | 6–10% | 68 weeks | SUSTAIN trials |
::alert info The headline result: Zepbound consistently outperforms all semaglutide-based drugs. In the REDEFINE 4 head-to-head trial, Zepbound achieved 25.5% weight loss versus CagriSema's 23.0% over 84 weeks. CagriSema failed to prove non-inferiority. ::/alert
That said, CagriSema still beat standard Wegovy and crushed Ozempic. In the REIMAGINE study, CagriSema delivered 14.2% weight loss versus 10.2% for semaglutide (Ozempic) in type 2 diabetes patients — a meaningful gap.
Side Effects: What to Expect
All GLP-1 drugs share a similar side effect profile. The gastrointestinal effects are the price of admission:
::versus CagriSema Side Effects vs Zepbound Side Effects
- Nausea: ~55% of patients | Nausea: ~30–35% of patients
- Vomiting: moderate | Vomiting: moderate
- Diarrhea: common | Diarrhea: common
- Constipation: common | Constipation: common
- Discontinuation rate: 5.9–8.4% | Discontinuation rate: ~6–7% ::/versus
CagriSema's nausea rate is notably higher than Zepbound's — likely because you're combining two mechanisms that both slow gastric emptying. Most side effects are mild to moderate and fade with dose escalation over weeks.
Serious risks (rare, all drugs): pancreatitis, gallbladder problems, and thyroid concerns. None of these drugs are recommended for people with a history of medullary thyroid cancer or MEN2 syndrome.
Cost and Insurance in 2026
Pricing is where the rubber meets the road. You can have the most effective drug in the world, but it's useless if you can't afford it.
::stats
- Oral Wegovy pill: ~$149/month (launched Jan 2026)
- Zepbound (Medicare): $50/month cap starting April 2026
- Zepbound (commercial): $25–$449/month depending on plan
- Wegovy injection: ~$1,300/month list price
- Ozempic: ~$900/month list price
- CagriSema: pricing TBD (not yet approved) ::/stats
Novo Nordisk slashed prices in late 2025, offering GLP-1 injectables through a direct-to-consumer marketplace at $245/month for eligible patients. Medicare coverage for GLP-1 weight loss drugs expanded significantly, with Zepbound capped at $50/month for beneficiaries starting April 2026.
CagriSema's eventual pricing is the big unknown. To justify a premium over Wegovy HD, Novo Nordisk will need to show advantages in cardiovascular outcomes or long-term data — the weight loss numbers alone don't justify a higher price tag since Zepbound already beats it.
Availability: What You Can Actually Get Right Now
| Drug | Status (March 2026) | How to Get It |
|---|---|---|
| Ozempic | ✅ Available (injection + oral tablets Q2 2026) | Prescription for type 2 diabetes |
| Wegovy | ✅ Available (injection, oral pill, HD dose) | Prescription for weight management |
| Zepbound | ✅ Available | Prescription for weight management |
| CagriSema | ❌ Not approved | FDA decision expected late 2026 |
Wegovy had the biggest year so far: the oral pill launched in January 2026, and the high-dose 7.2 mg injection (Wegovy HD) was approved on March 19, 2026, with U.S. launch expected April 2026.
::timeline
- Dec 2025: Oral Wegovy FDA approved; CagriSema NDA submitted
- Jan 2026: Oral Wegovy launches at $149/month
- Feb 2026: REDEFINE 4 results — CagriSema loses to Zepbound head-to-head
- Mar 19, 2026: Wegovy HD (7.2 mg) FDA approved
- Q2 2026: Oral Ozempic tablets launch in U.S.
- Apr 2026: Medicare $50/month Zepbound cap begins
- Late 2026: CagriSema FDA decision expected
- H2 2026: Higher-dose CagriSema trial begins ::/timeline
Who Should Consider Each Drug
::proscons CagriSema
- 22.7% weight loss — second only to Zepbound
- Novel dual-mechanism (GLP-1 + amylin)
- Beat Ozempic and Wegovy in trials
- Superior diabetes management vs Ozempic | Not yet FDA approved — can't get it yet | Failed non-inferiority vs Zepbound | Higher nausea rates (~55%) | Pricing unknown ::/proscons
::proscons Zepbound (Tirzepatide)
- Highest weight loss of any approved drug (22.5–25.5%)
- Dual GLP-1/GIP mechanism
- Medicare cap at $50/month starting April 2026
- Also approved for sleep apnea | Injection only (no pill option) | Supply constraints in some areas | Not approved for type 2 diabetes (that's Mounjaro) ::/proscons
::proscons Wegovy HD (7.2 mg)
- 20.7% weight loss — strongest approved Wegovy
- Established safety profile from years of data
- Oral pill option now available too
- Approved for cardiovascular risk reduction
| Still trails Zepbound by
4–5 percentage points | List price remains high ($1,300/month) | HD dose just approved — may take time to stock ::/proscons
::proscons Ozempic
- Well-established, years of safety data
- Oral tablets arriving Q2 2026
- Good for diabetes patients who also want weight loss
- Insurance coverage is broadest | Lowest weight loss of the group (6–10%) | Not approved for weight management | Off-label use may not be covered by insurance ::/proscons
The Bottom Line
If maximum weight loss is your priority: Zepbound wins. It's FDA-approved, available now, and consistently delivers the highest percentage of body weight reduction. The April 2026 Medicare price cap makes it more accessible than ever.
If you want an oral option: Oral Wegovy is a game-changer for people who hate needles. At $149/month and 13.6% average weight loss, it's the most convenient entry point.
If you have type 2 diabetes: CagriSema showed the best combined weight loss and blood sugar results in diabetes patients — but it's not available yet. In the meantime, Wegovy HD or Mounjaro (Zepbound's diabetes-approved sibling) are your best bets.
Should you wait for CagriSema? Probably not. The REDEFINE 4 trial showed it doesn't beat Zepbound, and it won't be available until late 2026 at the earliest. If you're considering treatment now, Zepbound or Wegovy HD are the proven winners.
::alert warning Important: All weight loss medications should be used under medical supervision alongside diet and exercise. These drugs are not cosmetic — they're prescribed for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related health conditions. Talk to your doctor about which option fits your health profile. ::/alert
The weight loss drug race is far from over. Novo Nordisk is already planning a higher-dose CagriSema trial for H2 2026, and Eli Lilly has an oral tirzepatide in the pipeline. By 2027, the options — and the competition driving prices down — will only accelerate.
